Impact of Comprehensive Molecular Tests on Antimicrobial Stewardship in Community-acquired Pneumonia (RADICAP)
Community-acquired Pneumonia
About this trial
This is an interventional treatment trial for Community-acquired Pneumonia focused on measuring antimicrobial stewardship, point-of-care test, comprehensive molecular tests, multiple PCR
Eligibility Criteria
Inclusion Criteria:
- Adult patients (18 years of age or older), of both sexes, hospitalized with a diagnosis of CAP in the first 24 hours of the admission.
- Patient or his legal representative gives the informed consent
Exclusion Criteria:
Patient with acute infection by SARS-CoV-2 being this defined as:
- Clinic of COVID-19 compatible, PCR positive for SARS-CoV-2 and negative serology for SARS-CoV-2.
OR
COVID-19 clinic compatible, PCR positive for SARS-CoV-2 (in the last 60 days) and positive serology for SARS-CoV-2.
- Pregnancy and / or nursing.
- Severe immunocompromised patients (chemotherapy or radiotherapy in the previous 90 days, use of immunosuppressive drugs, chronic use of corticosteroids at a minimum dose of 15 mg / day in the last two weeks, transplantation of hematopoietic progenitors, solid organ transplant, patients with HIV and CD4 count ≤ 200 cells / mm3).
- Imminent death (life expectancy ≤ 24 hours).
- Participation in another clinical trial of pharmacological treatment during the previous 3 months.
Sites / Locations
- Hospital Germans Trias i Pujol
- Moisés Broggi University Hospital
- SCIAS Hospital de Barcelona
- Hospital de Bellvitge
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Standard diagnostic tests
Experimental + standard diagnostic tests
Patients who will undergo only the standard diagnostic procedures
Patients will undergo described standard diagnostic procedures and in addition, real-time multiplex Protein Chain Reaction (PCR, FilmArray Pneumonia panel Plus ™, Biofire, BioMérieux).